Rheumatology Journals

Rheumatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Wiens A et al. – In the efficacy meta–analysis, a greater number of ETA–treated patients achieved the efficacy criteria within 6 months of treatment, where the relative risk (RR) was 2.94 for achieving ACR20, 5.28 for ACR50 and 4.83 for ACR70. After 1 year, the RR for achieving ACR20, ACR50 and ACR70 were 1.14, 1.36 and 1.56, respectively. This response rates were higher for ETA–treated patients in comparison with control group patients. For safety, there were no statistically significant differences between treated patients and controls. This was also confirmed by withdrawals as a result of adverse events, which were not statistically different between the two groups. However, more patients withdrew from control groups because of a lack of efficacy asEtanercept compared with ETA groups

Related Articles

Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09    Relevance Score: 71%

Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09    Relevance Score: 70%

Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09    Relevance Score: 70%

Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09    Relevance Score: 69%

Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09    Relevance Score: 69%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address